Phase I Study of Gilteritinib Combined With Induction/Consolidation Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia: Final Results

Source: 2020 American Society of Hematology Virtual Annual Meeting*
Download Slideset
December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
FLT3 inhibitor gilteritinib combined with induction and consolidation chemotherapy was well tolerated and showed good response in final results from this phase I study of patients with newly diagnosed FLT3-mutated acute myeloid leukemia.
Format: Microsoft PowerPoint (.ppt)
File Size: 388 KB
Released: December 7, 2020

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seagen
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings